Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
about
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applicationsCYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
P2860
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@en
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@nl
type
label
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@en
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@nl
prefLabel
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@en
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic profile and sa ...... ues, in HIV-infected subjects.
@en
P2093
Adam Croucher
Alan Winston
Borja Mora-Peris
David Back
George Scullard
Laura J Else
P2860
P304
P356
10.1093/JAC/DKT006
P407
P50
P577
2013-01-30T00:00:00Z